Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients

Shayna Stein, Rui Zhao, Hiroshi Haeno, Igor Vivanco, Franziska Michor

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models. However, EGFR inhibitors have shown little efficacy in the clinic, partly because of inappropriate dosing. Here, we developed a computational approach to model the in vitro cellular dynamics of the EGFR-mutant cell line SF268 in response to different lapatinib concentrations and dosing schedules. We then used this approach to identify an effective treatment strategy within the clinical toxicity limits of lapatinib, and developed a partial differential equation modeling approach to study the in vivo GBM treatment response by taking into account the heterogeneous and diffusive nature of the disease. Despite the inability of lapatinib to induce tumor regressions with a continuous daily schedule, our modeling approach consistently predicts that continuous dosing remains the best clinically feasible strategy for slowing down tumor growth and lowering overall tumor burden, compared to pulsatile schedules currently known to be tolerated, even when considering drug resistance, reduced lapatinib tumor concentrations due to the blood brain barrier, and the phenotypic switch from proliferative to migratory cell phenotypes that occurs in hypoxic microenvironments. Our mathematical modeling and statistical analysis platform provides a rational method for comparing treatment schedules in search for optimal dosing strategies for glioblastoma and other cancer types.

Original languageEnglish
Article numbere1005924
JournalPLoS Computational Biology
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 2018

Fingerprint

Growth Factors
Glioblastoma
Epidermal Growth Factor Receptor
Mathematical Modeling
Receptor
Appointments and Schedules
Schedule
mathematical models
Tumors
tumor
Tumor
neoplasms
modeling
Cell
Mutant
Inhibitor
Neoplasms
Cells
cell lines
inhibitor

All Science Journal Classification (ASJC) codes

  • Ecology, Evolution, Behavior and Systematics
  • Modelling and Simulation
  • Ecology
  • Molecular Biology
  • Genetics
  • Cellular and Molecular Neuroscience
  • Computational Theory and Mathematics

Cite this

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. / Stein, Shayna; Zhao, Rui; Haeno, Hiroshi; Vivanco, Igor; Michor, Franziska.

In: PLoS Computational Biology, Vol. 14, No. 1, e1005924, 01.2018.

Research output: Contribution to journalArticle

Stein, Shayna ; Zhao, Rui ; Haeno, Hiroshi ; Vivanco, Igor ; Michor, Franziska. / Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. In: PLoS Computational Biology. 2018 ; Vol. 14, No. 1.
@article{9c07a49adeb7441988038c002a170fa5,
title = "Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients",
abstract = "Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models. However, EGFR inhibitors have shown little efficacy in the clinic, partly because of inappropriate dosing. Here, we developed a computational approach to model the in vitro cellular dynamics of the EGFR-mutant cell line SF268 in response to different lapatinib concentrations and dosing schedules. We then used this approach to identify an effective treatment strategy within the clinical toxicity limits of lapatinib, and developed a partial differential equation modeling approach to study the in vivo GBM treatment response by taking into account the heterogeneous and diffusive nature of the disease. Despite the inability of lapatinib to induce tumor regressions with a continuous daily schedule, our modeling approach consistently predicts that continuous dosing remains the best clinically feasible strategy for slowing down tumor growth and lowering overall tumor burden, compared to pulsatile schedules currently known to be tolerated, even when considering drug resistance, reduced lapatinib tumor concentrations due to the blood brain barrier, and the phenotypic switch from proliferative to migratory cell phenotypes that occurs in hypoxic microenvironments. Our mathematical modeling and statistical analysis platform provides a rational method for comparing treatment schedules in search for optimal dosing strategies for glioblastoma and other cancer types.",
author = "Shayna Stein and Rui Zhao and Hiroshi Haeno and Igor Vivanco and Franziska Michor",
year = "2018",
month = "1",
doi = "10.1371/journal.pcbi.1005924",
language = "English",
volume = "14",
journal = "PLoS Computational Biology",
issn = "1553-734X",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients

AU - Stein, Shayna

AU - Zhao, Rui

AU - Haeno, Hiroshi

AU - Vivanco, Igor

AU - Michor, Franziska

PY - 2018/1

Y1 - 2018/1

N2 - Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models. However, EGFR inhibitors have shown little efficacy in the clinic, partly because of inappropriate dosing. Here, we developed a computational approach to model the in vitro cellular dynamics of the EGFR-mutant cell line SF268 in response to different lapatinib concentrations and dosing schedules. We then used this approach to identify an effective treatment strategy within the clinical toxicity limits of lapatinib, and developed a partial differential equation modeling approach to study the in vivo GBM treatment response by taking into account the heterogeneous and diffusive nature of the disease. Despite the inability of lapatinib to induce tumor regressions with a continuous daily schedule, our modeling approach consistently predicts that continuous dosing remains the best clinically feasible strategy for slowing down tumor growth and lowering overall tumor burden, compared to pulsatile schedules currently known to be tolerated, even when considering drug resistance, reduced lapatinib tumor concentrations due to the blood brain barrier, and the phenotypic switch from proliferative to migratory cell phenotypes that occurs in hypoxic microenvironments. Our mathematical modeling and statistical analysis platform provides a rational method for comparing treatment schedules in search for optimal dosing strategies for glioblastoma and other cancer types.

AB - Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models. However, EGFR inhibitors have shown little efficacy in the clinic, partly because of inappropriate dosing. Here, we developed a computational approach to model the in vitro cellular dynamics of the EGFR-mutant cell line SF268 in response to different lapatinib concentrations and dosing schedules. We then used this approach to identify an effective treatment strategy within the clinical toxicity limits of lapatinib, and developed a partial differential equation modeling approach to study the in vivo GBM treatment response by taking into account the heterogeneous and diffusive nature of the disease. Despite the inability of lapatinib to induce tumor regressions with a continuous daily schedule, our modeling approach consistently predicts that continuous dosing remains the best clinically feasible strategy for slowing down tumor growth and lowering overall tumor burden, compared to pulsatile schedules currently known to be tolerated, even when considering drug resistance, reduced lapatinib tumor concentrations due to the blood brain barrier, and the phenotypic switch from proliferative to migratory cell phenotypes that occurs in hypoxic microenvironments. Our mathematical modeling and statistical analysis platform provides a rational method for comparing treatment schedules in search for optimal dosing strategies for glioblastoma and other cancer types.

UR - http://www.scopus.com/inward/record.url?scp=85040940887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040940887&partnerID=8YFLogxK

U2 - 10.1371/journal.pcbi.1005924

DO - 10.1371/journal.pcbi.1005924

M3 - Article

C2 - 29293494

AN - SCOPUS:85040940887

VL - 14

JO - PLoS Computational Biology

JF - PLoS Computational Biology

SN - 1553-734X

IS - 1

M1 - e1005924

ER -